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Research
The World Health Organization (WHO 2011) 
has estimated that > 300 million people world­
wide suffer from type 2 diabetes; epidemiologi­
cal studies identify exposure to environ  mental 
toxicants as an independent risk factor for its 
development (Fujiyoshi et al. 2006; Kanagawa 
et al. 2008). Many structurally diverse com­
pounds function through activation of the aryl 
hydrocarbon receptor (AhR) to contribute 
to the development of diseases (Poland et al. 
1985; Safe 1986; Safe et al. 1985; Sato et al. 
2008; Schmidt and Bradfield 1996; Swanson 
2002; Van den Berg et al. 2006). The mecha­
nisms by which long­term AhR activation 
causes diabetes are currently unknown.
As a member of the PER­ARNT­SIM 
(PAS) domain family of transcriptional regu­
lators, ligand­activated AhR translocates to 
the nucleus and hetero  dimerizes with AhR 
nuclear translocator (ARNT), leading to toxic 
responses (Bock 1994). This well­described 
signaling pathway does not account for all 
effects of environmental toxicants, however. 
Crosstalk between AhR/ARNT and other 
nuclear receptors also contributes to toxicant­
induced diseases (Puga et al. 2009; Shimba 
and Watabe 2009).
AhR/ARNT and the clock proteins 
(circadian locomotor output cycles kaput; 
CLOCK) and BMAL1 [brain, muscle ARNT­
like protein 1; also called Arntl (aryl hydro­
carbon receptor nuclear translocator­like)] 
share structural similarities and exhibit diurnal 
changes in multiple tissues (Richardson et al. 
1998). AhR activation alters circadian rhyth­
micity and clock gene expression (Garrett and 
Gasiewicz 2006). Specifically, AhR activa­
tion disrupts CLOCK/BMAL1 activity and 
suppresses Period1 (Per1; also called period 
homolog 1) expression through inter  actions 
with BMAL1 (Xu et al. 2010). Chronic 
AhR activation also inhibits the responsive­
ness of the circadian clock to changes in 
environ  mental lighting (Mukai et al. 2008). 
Conversely, disruption of Per1 and Per2 
expression alters the AhR signaling pathway 
(Qu et al. 2007, 2010). Collectively, the data 
reveal a complex relationship between AhR 
signaling and clock genes.
The circadian clock is also linked to 
metabolism. Key metabolic proteins, such as 
peroxisome proliferator–activated receptor­α 
(PPAR­α), exhibit circadian variation. 
Disruption of CLOCK and BMAL1 alters 
glucose tolerance and regulation of key 
metabo  lism genes (Marcheva et al. 2010; 
Oishi et al. 2005; Turek et al. 2005). More 
important, circadian regulation of BMAL1 
and PPAR­α is inter  dependent (Canaple 
et al. 2006). Thus, PPAR­α may represent 
a critical link between the circadian clock 
and metabolism. The effects of PPAR­α on 
glucose metabolism are, however, equivocal. 
The PPAR­α agonist feno  fibrate increases 
insulin sensitivity and decreases glucose 
(Haluzik et al. 2006). In contrast, recent 
studies strongly associate PPAR­α signaling 
with insulin resistance (Bernal­Mizrachi et al. 
2003; Finck and Kelly 2002).
The aggregate literature compellingly 
implicates PPAR­α signaling, AhR activa­
tion, and circadian clock dysfunction in the 
development of type 2 diabetes in humans 
after exposure to environ  mental toxi  cants. 
AhR activation affects circadian rhyth  micity 
and expression of clock genes, which regulate 
PPAR­α. In the present study we investigated 
the involvement of BMAL1 and PPAR­α 
in glucose metabolism after manipulation of 
AhR signaling using small interfering RNA 
(siRNA) or AhR agonists, as well as in AhR­
deficient [knockout (KO)] mice. KO mice 
display increased responsiveness to insulin, 
decreased PPAR­α expression, and altered cir­
cadian rhythm of liver genes controlling glu­
cose and fatty acid metabolism. The growing 
pandemic of type 2 diabetes, in part due to 
exposure to environ  mental toxicants, remains 
a major challenge in human health. This study 
provides important insight into mechanisms 
by which toxicants, acting through AhR, pro­
duce type 2 diabetes.
Materials and Methods
Animals. Animals were treated humanely, 
with minimal suffering; animal protocols were 
approved by the institutional animal care 
committee of the Southern Illinois University 
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Ba c k g r o u n d: Numerous man-made pollutants activate the aryl hydrocarbon receptor (AhR) and 
are risk factors for type 2 diabetes. AhR signaling also affects molecular clock genes to influence 
glucose metabolism.
oB j e c t i v e: We investigated mechanisms by which AhR activation affects glucose metabolism.
Me t h o d s : Glucose tolerance, insulin resistance, and expression of peroxisome proliferator–activated 
receptor-α (PPAR-α) and genes affecting glucose metabolism or fatty acid oxidation and clock gene 
rhythms were investigated in wild-type (WT) and AhR-deficient [knockout (KO)] mice. AhR ago-
nists and small interfering RNA (siRNA) were used to examine the effect of AhR on PPAR-α expres-
sion and glycolysis in the liver cell line Hepa-1c1c7 (c7) and its c12 and c4 derivatives. Brain, muscle 
ARNT-like protein 1 (Bmal1) siRNA and Ahr or Bmal1 expression plasmids were used to analyze the 
effect of BMAL1 on PPAR-α expression in c7 cells.
re s u l t s: KO mice displayed enhanced insulin sensitivity and improved glucose tolerance, accom-
panied by decreased PPAR-α and key gluconeogenic and fatty acid oxidation enzymes. AhR ago-
nists increased PPAR-α expression in c7 cells. Both Ahr and Bmal1 siRNA reduced PPAR-α and 
metabo  lism genes. Moreover, rhythms of BMAL1 and blood glucose were altered in KO mice.
co n c l u s i o n s: These results indicate a link between AhR signaling, circadian rhythms, and glucose 
metabolism. Furthermore, hepatic activation of the PPAR-α pathway provides a mechanism under-
lying AhR-mediated insulin resistance.
key wo r d s: aryl hydrocarbon receptor, BMAL1, circadian rhythm, diabetes, dioxins, PPAR-α. 
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School of Medicine. Male and female mice 
4–24 weeks of age were used. Wild­type 
(WT; C57Bl/6J) and KO (Bradfield strain; 
Schmidt et al. 1996) littermates, obtained 
originally from R. Petersen (University of 
Wisconsin, Madison, WI, USA), were bred 
in our colony. Animals entrained to 12/12­hr 
light/dark cycles were decapitated, and liv­
ers were collected at 4­hr intervals starting at 
zeitgeber time (ZT) 0, the time of lights on, 
or ZT12, the time of lights off. Tissues were 
snap­frozen in liquid nitrogen and stored at 
–80°C until use.
Cell culture and siRNA treatment. The 
mouse Hepa­1c1c7 (c7), c12, and c4 liver 
cell lines (ATCC, Manassas, VA, USA) were 
cultured in DMEM (Dulbecco’s modified 
Eagle’s medium) Reduced Serum (HyClone, 
Logan, UT, USA) with 7.5% bovine growth 
serum (HyClone) and penicillin/streptomy­
cin/amphotericin (MP Biomedicals, Solon, 
OH, USA) at 37°C in a humidified, 5% 
CO2 atmosphere. All culture experiments 
were repeated at least three times, with 
doses of drugs as indicated in the figures. 
Cultures were treated with β­napthoflavone 
(BNF; Sigma Chemical Co., St. Louis, MO, 
USA), 2,3,7,8­tetrachlorodibenzo­p­dioxin 
(TCDD) (L. Hansen, University of Illinois 
at Urbana­Champaign, Urbana, IL, USA), 
GW6471 (Sigma), and/or α­napthoflavone 
(ANF; Sigma). DMSO was the vehicle for all 
controls. Negative, Ahr, and Bmal1 siRNAs 
[50 nM; Invitrogen, Carlsbad, CA, USA; for 
sequences, see Supplemental Material, Table, 
(http://dx.doi.org/10.1289/ehp.1103593)] 
were delivered into cells (4.0 × 104) using 
Lipofectamine 2000 (Invitrogen) as described 
previously (Wang et al. 2009). 
Plasmid transfection. Mouse Bmal1 cloned 
into pCS2+MTK vector (from P. Sassone­
Corsi, University of California–Irvine, Irvine, 
CA, USA) and human Ahr cloned in pcDNA3 
vector (from G. Perdew, Pennsylvania State 
University, University Park, PA, USA) were 
transfected with or without siRNA into c7 
cells using Lipofectamine 2000 and cultured 
for 48 hr.
RNA extraction and analysis. Total 
RNA was extracted from liver using TRI­
Reagent (Sigma) according to the manufac­
turer’s protocol. After cDNA synthesis using 
Oligo(dT)15 Primer (Promega protocol; 
Promega, Madison, WI, USA), 5 μL cDNA 
(1:5 or no dilution for Ppara in cell experi­
ments) was used for quantitative polymerase 
chain reaction (qPCR) using SYBR green 
(Quanta Biosciences, Gaithersburg, MD, 
USA) in a Smart Cycler rapid thermal cycler 
(Cepheid, Sunnyvale, CA, USA). Each assay 
included a no­reverse­transcriptase negative 
control. Primer sequences are given in the 
Supplemental Material, Table (http://dx.doi.
org/10.1289/ehp.1103593). Relative standard 
curves were created for each gene primer as 
previously described (Xu et al. 2010); β­actin 
was used for normalization.
Protein extraction and analysis. Cell lines 
and liver tissue were harvested and homoge­
nized in lysis buffer; total protein (80–100 μg) 
was separated using SDS­PAGE. Membranes 
were immuno  blotted with anti  bodies to 
PPAR­α (1:1,000; Sigma) and AhR (1:1,000; 
Enzo Life Sciences, Farmingdale, NY, USA). 
Glucose tolerance test (GTT) and insulin 
tolerance test (ITT). Studies were performed 
as described previously (Finck et al. 2005). 
The GTT and ITT were separated by at least 
1 week. For the GTT, mice were injected 
with a 10% solution of d­glucose (1 g/kg 
body weight) after an overnight fast. For the 
ITT, mice received an intra  peritoneal injec­
tion of porcine insulin (0.75 U/kg; Sigma) 
after a 6­hr fast. Tail blood was assayed using 
a TRUEtrack blood glucose meter (Nipro 
Diagnostics Inc., Fort Lauderdale, FL, USA).
Lactate concentration measurements. 
Cell medium and cell lysate were collected; 
lactate concentrations were measured using 
the L­Lactate Assay Kit for a 96­well plate 
(Eton Bioscience Inc., San Diego, CA, USA) 
according to the manufacturer’s instructions. 
Statistics. We used Student’s t­test and 
analysis of variance for statistical analysis; 
p < 0.05 was considered statistically significant. 
All data represent mean ± SE. 
Figure 1. Glucose tolerance and insulin sensitivity in WT and KO mice. (A) GTT results for WT (n = 7) and KO (n = 4) mice. (B) Insulin levels in serum of WT (n = 4) 
and KO (n = 4) mice. (C) ITT results for WT (n = 8) and KO (n = 5) mice. Data are mean ± SE. 
*p < 0.05 compared with WT mice. 
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Figure 2. Expression of Ahr, Ppara, and metabolism genes in WT and KO mice. (A) qPCR analysis of Ahr mRNA. (B) PPAR-α protein (top; representative immuno-
blot from three WT and two KO animals) and Ppara mRNA (bottom) in WT and KO mice. (C) qPCR analysis of hepatic β-oxidation and gluconeogenic genes. All 
samples are from liver of WT (n = 8) and KO (n = 10) mice, collected at ZT8. Data are mean ± SE. 
*p < 0.05, **p < 0.01, and #p < 0.001 compared with WT mice. 
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Results
Insulin sensitivity in Ahr-null mice. We 
recorded weights of WT and KO mice monthly 
and found no effect of genotype on weight 
[see Supplemental Material, Figure 1 (http://
dx.doi.org/10.1289/ehp.1103593)]. Fasting 
glucose levels were the same in WT and KO 
mice (Figure 1A). However, during GTT, glu­
cose levels remained lower in KO mice for up 
to 180 min (Figure 1A). Serum insulin levels 
showed no significant difference between WT 
and KO mice at 20 min after glucose challenge 
(Figure 1B), suggesting that insulin release is 
similar in the two mouse strains. However, KO 
mice exhibited a larger reduction in glucose 
than did WT mice for up to 120 min after insu­
lin challenge (Figure 1C), indicating enhanced 
insulin sensitivity in the KO mice.
Expression of key metabolic genes in 
KO and WT mice. Ahr mRNA was essen­
tially undetectable in KO mice (Figure 2A). 
Ppara mRNA and PPAR­α protein, which 
regulates fatty acid and glucose metabolism, 
were reduced in KO mouse liver (Figure 2B). 
Transcripts of the PPAR­α target genes 
acyl­CoA oxidase (Aco) and carnitine palmi­
toyl transferase 1b (Cpt1b) were decreased 
by 50% and 70%, respectively, in KO mice 
(Figure 2C). Transcripts for phospho  enol­
pyruvate carboxy  kinase (Pepck) and glucose 
6­phosphatase (G6pase), which encode gluco­
neo  genic enzymes, were also significantly 
reduced in the liver of KO mice (Figure 2C). 
In contrast, pyruvate dehydrogenase kinase, 
isozyme 4 (Pdk4) transcript, which encodes an 
inhibitor of glucose oxidation, did not change 
(Figure 2C). 
AhR/ARNT signal-pathway–dependent 
induction of PPAR-α. Knockout of Ppara 
prevents insulin resistance in mice (Guerre­
Millo et al. 2001; Tordjman et al. 2001; 
Xu et al. 2004). We determined the role of 
PPAR­α in AhR­mediated changes in glu­
cose metabolism using cell lines (c7, c12, 
and c4), which have been extensively used to 
explore AhR/ARNT signaling. c12 cells are 
c7 derivatives that express extremely low levels 
of AhR (Figure 3A) (Zhang et al. 1996). The 
c4 cells are c7 derivatives that lack functional 
ARNT (Numayama­Tsuruta et al. 1997). As 
expected, the AhR target gene Cyp1a1 (cyto­
chrome P450, family 1, subfamily a, poly­
peptide 1) was significantly reduced in c12 
and c4 cells compared with c7 cells after treat­
ment with the AhR agonist BNF (Figure 3B). 
BNF induced Ppara mRNA (Figure 3C) and 
PPAR­α protein expression (Figure 3D) only 
in c7 cells (Figure 3C,D). BNF also increased 
Ppara mRNA levels in WT but not in KO 
mice (Figure 4A). Similar to results in KO 
mice, basal Ppara transcripts were significantly 
lower in c12 cells than in c7 cells (Figure 3C), 
and the AhR antagonist ANF blocked BNF­
induced PPAR­α expression (Figure 4B). AhR 
silencing in c7 cells significantly decreased 
Ppara and Aco transcription (Figure 4C).
Another AhR ligand, TCDD, also 
increased Ppara mRNA in c7 cells, which 
returned to baseline by 24 hr [see Supplemental 
Material, Figure 2a (http://dx.doi.org/10.1289/
ehp.1103593)]. In contrast, BNF caused 
a sustained increase in Ppara mRNA (see 
Supplemental Material, Figure 2a). AhR deg­
radation, which was significantly greater after 
TCDD treatment (see Supplemental Material, 
Figure 2b), may explain the difference between 
agonists. However, both TCDD and BNF 
induced Cyp1a1 for the full 24­hr period (see 
Supplemental Material, Figure 2c). Thus, AhR/
ARNT signaling regulates PPAR­α expression.
PPAR-α–dependent regulation of AhR 
in glucose metabolism. Increased PPAR­α in 
adipo  cytes increases fatty acid uptake and oxi­
dation and suppresses glucose use (Finck et al. 
2005; Ribet et al. 2010). Because PPAR­α 
levels are regulated by AhR, we examined 
the effect of AhR activation on glycolysis. 
BNF (10 μM, 48 hr) reduced intra  cellular 
Figure 3. Role of PPAR-α in Ahr-mediated changes in c7, c12, and c4 cells treated with DMSO or 10 µM 
BNF. (A) AhR protein (top) and Ahr mRNA (bottom). (B and C) qPCR analysis of Cyp1a1 (B) and Ppara (C). 
(D) Immunoblot analysis of PPAR-α protein. n = 3 for each cell type and treatment.
*p < 0.05 compared with c7 cells. **p < 0.01 compared with DMSO. #p < 0.001 compared with c7 cells. ##p < 0.01 compared with 
c7 cells. †p < 0.05 compared with DMSO. 
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Figure 4. Effect of AhR signaling on PPAR-α expression. (A) qPCR analysis of Ppara (top) and Cyp1a1 (bot-
tom) in WT and KO mice (n = 4 each) after treatment with oil vehicle or BNF for 24 hr at ZT0. (B) Immuno-
blot showing PPAR-α protein in c7 cells treated with or without DMSO alone or with 10 μM BNF and/or 
500 nM ANF. (C) qPCR analysis of Ahr, Ppara, and Aco in Ahr-silenced c7 cells (n = 3 each) and immuno-
blot of Ppara and AhR. n = 3 for each cell type and treatment. Data are mean ± SE. Neg, negative.
*p < 0.05 compared with WT oil. #p < 0.001 compared with WT oil. †p < 0.05 compared with Neg siRNA. 
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lactate concentration in c7 cells but not in 
c12 or c4 cells (Figure 5A). Ahr silencing 
significantly increased lactate concentrations 
in c7 cells, confirming that AhR regulates 
glycolysis (Figure 5B). To verify the impor­
tance of PPAR­α in glycolysis, we used 
GW6471, a PPAR­α antagonist (Xu et al. 
2002). GW6471 did not significantly alter 
basal levels of intra  cellular lactate (p = 0.0624) 
but attenuated the BNF­induced decrease in 
intra  cellular lactate concentration (Figure 5C). 
Pdk4 transcripts were decreased in Ahr­
silenced c7 cells (Figure 5D).
Involvement of BMAL1 in the regulation 
of AhR effects on PPAR-α. CLOCK/BMAL1   
regu  lates PPAR­α expression (Oishi et al. 
2005). To confirm that BMAL1 regu  lates 
PPAR­α, we silenced Bmal1 with siRNA. 
As expected, reduction of BMAL1 decreased 
PPAR­α and its target gene Aco (Figure 6A). 
Because BMAL1 associates with AhR (Xu et al. 
2010), we examined how silencing of each 
affects PPAR­α expression. Interestingly, Bmal1 
silencing significantly reduced Ahr mRNA and 
suppressed Cyp1a1 (Figure 6A). Ahr silenc­
ing also inhibited Bmal1 mRNA (Figure 6A). 
Simultaneous silencing of Bmal1 and Ahr was 
not additive (Figure 6B). Furthermore, Bmal1 
silencing partially blocked PPAR­α induction 
by BNF (Figure 6C) but did not affect Cyp1a1 
(Figure 6D), showing that BMAL1 is needed 
for AhR­mediated PPAR­α expression.
Because BMAL1 and AhR both up­ 
regulate PPAR­α, we cotransfected Ahr 
siRNA and Bmal1 plasmid or Bmal1 siRNA 
and Ahr plasmid and measured Ppara mRNA 
levels. Overexpression of AhR increased 
Cyp1a1 mRNA levels, and Bmal1 trans­
fection increased Bmal1 mRNA levels [see 
Supplemental Material, Figure 3b,c (http://
dx.doi.org/10.1289/ehp.1103593)]. However, 
transfection of Ahr and Bmal1 plasmids did 
not rescue Ppara mRNA down­regulation 
induced by silencing either Bmal1 or Ahr (see 
Supplemental Material, Figure 3a).
Altered circadian rhythm in KO mice. To 
link AhR to clock and glucose metabo  lism, 
we examined rhythms in clock and metabolic 
genes and blood glucose in KO mice. Ppara 
transcript rhythmicity in WT mice was consis­
tent with results of a previous study (Oishi et al. 
2005) but was altered in KO mice (Figure 7A); 
the amplitude of the Ppara rhythm was signifi­
cantly blunted in KO mice. Rhythms of Bmal1 
and Per1 mRNA were also slightly altered in 
KO mice (Figure 7B,C) specifically at ZT4 
and ZT8. The rhythm of blood glucose was 
also attenuated (Figure 7D); glucose in KO 
mice was almost significantly lower than WT 
mice at ZT22 (p = 0.052).
Discussion
We examined the interactions of AhR with 
PPAR­α, glucose metabolism, and circadian 
rhythm in liver (Figure 8). Liver PPAR­α 
expression and rhythms are altered after AhR 
deletion, demon  strating that AhR may be an 
integral regulator of PPAR­α and may influ­
ence liver circadian rhythms (Figure 8, solid 
arrows). PPAR­α influences both BMAL1 
and AhR (Canaple et al. 2006; Villard et al. 
2007; see also Figure 6). PPAR­α has been 
associated with development of insulin resis­
tance (Finck et al. 2005; Koo et al. 2004).
KO mice have enhanced insulin sensitiv­
ity and improved glucose tolerance (Figure 1), 
accompanied by decreased expression of Ppara 
and metabolism genes Aco, Cpt1b, G6pase, and 
Pepck (Figures 2 and 4B). Long­term activa­
tion of AhR results in increased peripheral fat 
Figure 5. Effect of AhR activation on glycolysis. (A) Intracellular lactate concentrations in c7, c12, and c4 
cells after treatment with DMSO or 10 μM BNF. (B) Lactate levels in Ahr-silenced c7 cells. (C) Lactate in c7 
cells after treatment with DMSO, 10 μM BNF, 10 μM GW6471, or BNF + GW6471. (D) qPCR analysis of Pdk4 
mRNA in Ahr-silenced c7 cells. Data are mean ± SE; n = 3 for each cell type and treatment. Neg, negative.
*p < 0.05 compared with DMSO. †p < 0.05 compared with Neg siRNA. 
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mobilization and decreased body fat (Lee et al. 
2010). ACO and CPT1b are key enzymes 
regulating fatty acid β­oxidation. PPAR­α 
activation increases PEPCK and G6Pase 
expression, which causes hyper  glycemia and 
insulin resistance (Bernal­Mizrachi et al. 2003). 
Collectively, these results suggest that KO 
mice are protected against insulin resistance. 
Reduced PPAR­α provides a possible mecha­
nism for this protection.
AhR activation up­regulates Ppara when 
AhR signaling is intact (Figure 3C,D). BNF 
also stimulates Ppara expression in WT but 
not in KO mice (Figure 4A). Moreover, the 
AhR antagonist ANF blocks the BNF induc­
tion of PPAR­α (Figure 4B). Thus, PPAR­α is 
regulated by AhR/ARNT. Similarly, the AhR 
ligand 3­methyl  cholanthrene increases PPAR­α 
expression in C57Bl/6J mice (Kawano et al. 
2010). In contrast, the AhR ligand Sudan III 
inhibits PPAR­α expression in rats and HepG2 
hepatocellular liver carcinoma cells (Shaban 
et al. 2004). Results of those studies do not 
necessarily refute our findings because some 
AhR ligands can activate other signaling path­
ways (Terzuoli et al. 2010) Transgenic mice 
with constitutively active AhR have decreased 
PPAR­α levels (Lee et al. 2010). The constitu­
tively active AhR is missing the minimal ligand­
binding domain and binds only to proto  typical 
dioxin response elements. Although AhR bind­
ing to alternative promoter elements remains 
under  investigated, AhR can interfere with the 
BMAL1/CLOCK binding to an E­box (Xu 
et al. 2010). BMAL1/CLOCK also regulates 
PPAR­α expression through E­box elements 
(Oishi et al. 2005). Thus, constitutively active 
AhR may differ from native AhR activation.
TCDD  induced  Ppara  mRNA  in 
c7 cells, but Ppara returned to basal lev­
els after 24 hr, possibly due to degradation 
of AhR protein after TCDD treatment [see 
Supplemental Material, Figure 2a,b (http://
dx.doi.org/10.1289/ehp.1103593)]. However, 
Cyp1a1 continually increased after BNF or 
TCDD treatment (see Supplemental Material, 
Figure 2c), suggesting that mechanisms regulat­
ing Ppara and Cyp1a1 after AhR activation are 
different. PPAR­α activation inhibits glycolysis 
(Ribet et al. 2010); Ppara‑null mice exhibit 
higher rates of glucose metabolism (Knauf 
et al. 2006; Walker et al. 2007). BNF inhibited 
glycolysis in c7 cells (Figure 5A); further  more, 
the PPAR­α antagonist GW6471 blocked this 
inhibition (Figure 5C). AhR knockdown ele­
vated lactate concentrations (Figure 5B) and 
inhibited Pdk4 mRNA levels (Figure 5D). In 
contrast Pdk4 mRNA levels did not change 
in KO mice (Figure 2C), perhaps because of 
compensatory mechanisms.
This study confirms that BMAL1 regu­
lates PPAR­α. Bmal1 silencing decreases c7 
Ppara and Aco (Figure 6A). Surprisingly, 
Ahr mRNA is also decreased after Bmal1 
silencing (Figure 6A). Cyp1a1 is suppressed, 
indicating that BMAL1 depletion inhibits 
AhR (Figure 6A). Conversely, Bmal1 mRNA 
significantly decreases in Ahr­silenced cells 
(Figure 6A). Simultaneous silencing of Ahr and 
Bmal1 does not enhance the inhibitory effect 
on PPAR­α caused by AhR or BMAL1 knock­
down alone (Figure 6B). In Bmal1­silenced 
Figure 7. Effect of AhR on (A–C) circadian rhythm of Ppara (A), Bmal1 (B), and Per1 (C) expression and 
on (D) rhythm of blood glucose in KO and WT mice. Data are mean ± SE. For A–C, n = 5 KO mice and 4 WT 
mice; for D, n = 6 for each.
*p < 0.05, **p < 0.01, and #p < 0.001 for peak compared with trough. ##p < 0.05 compared with WT. †p < 0.01 compared with WT. 
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c7 cells, the induction of PPAR­α by BNF is 
partially blocked (Figure 6C). Cotransfection 
of Ahr siRNA and Bmal1 plasmid or Bmal1 
siRNA and Ahr plasmid does not rescue Ppara 
down­regulation induced by silencing of Ahr 
or Bmal1 [see Supplemental Material, Figure 3 
(http://dx.doi.org/10.1289/ehp.1103593)]. 
Collectively, these results provide a possible 
mechanism for AhR and BMAL1 to regulate 
PPAR­α. Because PPAR­α regulates BMAL1, 
AhR, and CYP1A1 (Canaple et al. 2006; Seree 
et al. 2004; Villard et al. 2007), we speculate 
that the inhibitory effect of Bmal1 silencing 
on AhR and CYP1A1 may be mediated by 
PPAR­α. Similarly, the reduction in BMAL1 
caused by Ahr silencing may depend on 
PPAR­α. AhR and PPAR­α may provide posi­
tive feedback to the liver circadian clock.
AhR and ARNT exhibit strong rhythmicity 
in liver (Mukai et al. 2008), but the under  lying 
mechanism remains unclear. Disruption of Per1 
and Per2 alters AhR (Qu et al. 2007). AhR acti­
vation changes the expression of liver Per1 and 
BMAL1. Although in KO mice Bmal1 and 
Per1 rhythms are only modestly altered, the 
diurnal variations in blood glucose and Ppara 
are significantly changed (Figure 7). Although 
fasting glucose levels did not change, KO mice 
showed an enhanced glucose and insulin sensi­
tivity compared with WT mice (Figure 1A,C). 
Thus, AhR may regulate circadian clock output 
in peripheral clock systems such as the liver.
Conclusions
Glucose metabolism in KO mice is remi­
niscent of that in PPAR­α–deficient mice; 
AhR clearly regulates PPAR­α. Future studies 
will explore how AhR and BMAL1 regulate 
PPAR­α expression in other peripheral tis­
sues, such as pancreas, muscle, and adipose. It 
will also be important to develop in vivo toxi­
cant exposure models to mimic develop  ment 
of diabetes caused by chronic environmental 
pollutant exposure in humans.
The epidemic of obesity and diabetes is 
widely recognized as an emerging public health 
problem of enormous magnitude. AhR activa­
tion, although much less widely acknowledged, 
is also epidemiologically associated with diabetes 
(Bock 1994). These pollutants are ubiquitous in 
modern life, and their effects profoundly influ­
ence human health. Understanding the mecha­
nisms involved in AhR­induced diabetes has the 
potential to revolutionize our under  standing of 
type 2 diabetes.
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